FAE Stock Overview
Researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Faes Farma, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.47 |
| 52 Week High | €3.83 |
| 52 Week Low | €2.91 |
| Beta | 0.50 |
| 11 Month Change | -6.09% |
| 3 Month Change | -4.54% |
| 1 Year Change | 12.85% |
| 33 Year Change | 2.06% |
| 5 Year Change | -33.40% |
| Change since IPO | 242.24% |
Recent News & Updates
Faes Farma, S.A. (BME:FAE) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 03
Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Recent updates
Faes Farma, S.A. (BME:FAE) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Nov 03Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316
Dec 18Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316
Dec 04Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?
Nov 24Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly
May 03Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?
Sep 21Is Faes Farma (BME:FAE) A Risky Investment?
Aug 03Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth
Jun 17Is Faes Farma (BME:FAE) Using Too Much Debt?
Mar 27Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14
Dec 13Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17
Nov 29Is Faes Farma (BME:FAE) A Risky Investment?
Sep 21Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year
Jul 31Is Faes Farma (BME:FAE) Using Too Much Debt?
May 01Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)
Apr 07Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?
Mar 22Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations
Mar 06Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment
Feb 22I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease
Jan 16Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly
Dec 08Shareholder Returns
| FAE | ES Pharmaceuticals | ES Market | |
|---|---|---|---|
| 7D | -1.7% | -3.2% | 0.2% |
| 1Y | 12.8% | 11.9% | 17.0% |
Return vs Industry: FAE matched the Spanish Pharmaceuticals industry which returned 11.9% over the past year.
Return vs Market: FAE underperformed the Spanish Market which returned 17% over the past year.
Price Volatility
| FAE volatility | |
|---|---|
| FAE Average Weekly Movement | 1.8% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 2.9% |
| 10% most volatile stocks in ES Market | 5.4% |
| 10% least volatile stocks in ES Market | 0.6% |
Stable Share Price: FAE has not had significant price volatility in the past 3 months compared to the Spanish market.
Volatility Over Time: FAE's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1933 | 1,762 | n/a | faesfarma.com |
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials worldwide. It operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It offers products for various therapeutic areas.
Faes Farma, S.A. Fundamentals Summary
| FAE fundamental statistics | |
|---|---|
| Market cap | €1.08b |
| Earnings (TTM) | €97.59m |
| Revenue (TTM) | €504.04m |
11.1x
P/E Ratio2.1x
P/S RatioIs FAE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FAE income statement (TTM) | |
|---|---|
| Revenue | €504.04m |
| Cost of Revenue | €169.88m |
| Gross Profit | €334.16m |
| Other Expenses | €236.57m |
| Earnings | €97.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.31 |
| Gross Margin | 66.30% |
| Net Profit Margin | 19.36% |
| Debt/Equity Ratio | 6.9% |
How did FAE perform over the long term?
See historical performance and comparison